Garg Amit X, Suri Rita S, Barrowman Nick, Rehman Faisal, Matsell Doug, Rosas-Arellano M Patricia, Salvadori Marina, Haynes R Brian, Clark William F
Division of Adult and Pediatric Nephrology, University of Western Ontario, London, Canada.
JAMA. 2003 Sep 10;290(10):1360-70. doi: 10.1001/jama.290.10.1360.
The long-term renal prognosis of patients with diarrhea-associated hemolytic uremic syndrome (HUS) remains controversial.
To quantify the long-term renal prognosis of patients with diarrhea-associated HUS and to identify reasons for different estimates provided in the literature.
We searched MEDLINE and Experta Medica (EMBASE) bibliographic databases and conference proceedings, and we contacted experts until February 2003. We also searched the Institute for Scientific Information index and reference lists of all studies that fulfilled our eligibility criteria. The search strategy included the terms hemolytic-uremic syndrome, purpura, thrombotic thrombocytopenic, Escherichia coli O157, longitudinal studies, kidney diseases, hypertension, and proteinuria
Any study that followed up 10 or more patients with primary diarrhea-associated HUS for at least 1 year for renal sequelae.
Two authors independently abstracted data on study and patient characteristics, renal measures, outcomes, and prognostic features. Disagreements were resolved by a third author or by consensus.
Forty-nine studies of 3476 patients with a mean follow-up of 4.4 years (range, 1-22 years at last follow-up) from 18 countries, 1950 to 2001, were summarized. At the time of recruitment, patients were aged 1 month to 18 years. In the different studies, death or permanent end-stage renal disease (ESRD) ranged from 0% to 30%, with a pooled incidence of 12% (95% confidence interval [CI], 10%-15%). A glomerular filtration rate lower than 80 mL/min per 1.73 m2, hypertension, or proteinuria was extremely variable and ranged from 0% to 64%, with a pooled incidence of 25% (95% CI, 20%-30%). A higher severity of acute illness was strongly associated with worse long-term prognosis. Studies with a higher proportion of patients with central nervous system symptoms (coma, seizures, or stroke) had a higher proportion of patients who died or developed permanent ESRD at follow-up (explaining 44% of the between-study variability, P =.01). Studies with a greater proportion of patients lost to follow-up also described a worse prognosis (P =.001) because these patients were typically healthier than those followed up. One or more years after diarrhea-associated HUS, patients with a predicted creatinine clearance higher than 80 mL/min per 1.73 m2, no overt proteinuria, and no hypertension appeared to have an excellent prognosis.
Death or ESRD occurs in about 12% of patients with diarrhea-associated HUS, and 25% of survivors demonstrate long-term renal sequelae. Patients lost to follow-up contribute to worse estimates in some studies. The severity of acute illness, particularly central nervous system symptoms and the need for initial dialysis, is strongly associated with a worse long-term prognosis.
腹泻相关性溶血尿毒综合征(HUS)患者的长期肾脏预后仍存在争议。
量化腹泻相关性HUS患者的长期肾脏预后,并找出文献中不同评估结果的原因。
我们检索了MEDLINE和医学专家数据库(EMBASE)的文献数据库及会议论文集,并在2003年2月前与专家进行了联系。我们还检索了科学信息研究所的索引以及所有符合我们纳入标准的研究的参考文献列表。检索策略包括以下术语:溶血尿毒综合征、紫癜、血栓性血小板减少性紫癜、大肠杆菌O157、纵向研究、肾脏疾病、高血压和蛋白尿。
任何对10例或更多原发性腹泻相关性HUS患者进行至少1年肾脏后遗症随访的研究。
两位作者独立提取有关研究和患者特征、肾脏指标、结局及预后特征的数据。分歧由第三位作者解决或通过协商一致解决。
总结了1950年至2001年来自18个国家的3476例患者的49项研究,平均随访4.4年(最后一次随访范围为1至22年)。入组时患者年龄为1个月至18岁。在不同研究中,死亡或永久性终末期肾病(ESRD)的发生率在0%至30%之间,合并发生率为12%(95%置信区间[CI],10% - 15%)。肾小球滤过率低于80 mL/min/1.73 m²、高血压或蛋白尿的发生率差异极大,在0%至64%之间,合并发生率为25%(95% CI,20% - 30%)。急性疾病的严重程度越高,长期预后越差。中枢神经系统症状(昏迷、癫痫发作或中风)患者比例较高的研究中,随访时死亡或发生永久性ESRD的患者比例也较高(解释了研究间差异的44%,P = 0.01)。失访患者比例较高的研究也显示预后较差(P = 0.001),因为这些患者通常比接受随访的患者更健康。腹泻相关性HUS发生1年或更长时间后,预测肌酐清除率高于80 mL/min/1.73 m²、无明显蛋白尿且无高血压的患者预后似乎良好。
腹泻相关性HUS患者中约12%发生死亡或ESRD,25%的幸存者有长期肾脏后遗症。在一些研究中,失访患者导致了较差的评估结果。急性疾病的严重程度,尤其是中枢神经系统症状和初始透析的需求,与较差的长期预后密切相关。